TARS Quote, Financials, Valuation and Earnings

Celcuity, Inc. has a net margin of -10.6% compared to Tarsus Pharmaceuticals, Inc.'s net margin of --. Tarsus Pharmaceuticals, Inc.'s return on equity of -27.56% beat Celcuity, Inc.'s return on equity of -158.5%.

Tarsus Pharmaceuticals, Inc. has a consensus price target of $87.50, signalling upside risk potential of 7.49%. On the other hand Celcuity, Inc. has an analysts' consensus of $110.50 which suggests that it could grow by 9.23%. Given that Celcuity, Inc. has higher upside potential than Tarsus Pharmaceuticals, Inc., analysts believe Celcuity, Inc. is more attractive than Tarsus Pharmaceuticals, Inc..

Tarsus Pharmaceuticals, Inc. has a beta of 0.745, which suggesting that the stock is 25.508% less volatile than S&P 500. In comparison Celcuity, Inc. has a beta of 0.209, suggesting its less volatile than the S&P 500 by 79.061%.

Tarsus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Celcuity, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tarsus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Celcuity, Inc. pays out -- of its earnings as a dividend.

Tarsus Pharmaceuticals, Inc. quarterly revenues are $118.7M, which are larger than Celcuity, Inc. quarterly revenues of --. Tarsus Pharmaceuticals, Inc.'s net income of -$12.6M is higher than Celcuity, Inc.'s net income of -$43.8M. Notably, Tarsus Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Celcuity, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tarsus Pharmaceuticals, Inc. is 9.05x versus -- for Celcuity, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals, Inc. has a net margin of -10.6% compared to Tarsus Pharmaceuticals, Inc.'s net margin of -82.06%. Tarsus Pharmaceuticals, Inc.'s return on equity of -27.56% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Tarsus Pharmaceuticals, Inc. has a consensus price target of $87.50, signalling upside risk potential of 7.49%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $87.99 which suggests that it could grow by 10.58%. Given that Ionis Pharmaceuticals, Inc. has higher upside potential than Tarsus Pharmaceuticals, Inc., analysts believe Ionis Pharmaceuticals, Inc. is more attractive than Tarsus Pharmaceuticals, Inc..

Tarsus Pharmaceuticals, Inc. has a beta of 0.745, which suggesting that the stock is 25.508% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.45%.

Tarsus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tarsus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Tarsus Pharmaceuticals, Inc. quarterly revenues are $118.7M, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Tarsus Pharmaceuticals, Inc.'s net income of -$12.6M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Tarsus Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tarsus Pharmaceuticals, Inc. is 9.05x versus 13.55x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Liquidia Corp. has a net margin of -10.6% compared to Tarsus Pharmaceuticals, Inc.'s net margin of -6.5%. Tarsus Pharmaceuticals, Inc.'s return on equity of -27.56% beat Liquidia Corp.'s return on equity of -221.75%.

Tarsus Pharmaceuticals, Inc. has a consensus price target of $87.50, signalling upside risk potential of 7.49%. On the other hand Liquidia Corp. has an analysts' consensus of $39.00 which suggests that it could grow by 27.43%. Given that Liquidia Corp. has higher upside potential than Tarsus Pharmaceuticals, Inc., analysts believe Liquidia Corp. is more attractive than Tarsus Pharmaceuticals, Inc..

Tarsus Pharmaceuticals, Inc. has a beta of 0.745, which suggesting that the stock is 25.508% less volatile than S&P 500. In comparison Liquidia Corp. has a beta of 0.482, suggesting its less volatile than the S&P 500 by 51.777%.

Tarsus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Liquidia Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tarsus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Liquidia Corp. pays out -- of its earnings as a dividend.

Tarsus Pharmaceuticals, Inc. quarterly revenues are $118.7M, which are larger than Liquidia Corp. quarterly revenues of $54.3M. Tarsus Pharmaceuticals, Inc.'s net income of -$12.6M is lower than Liquidia Corp.'s net income of -$3.5M. Notably, Tarsus Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Liquidia Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tarsus Pharmaceuticals, Inc. is 9.05x versus 42.63x for Liquidia Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Precigen, Inc. has a net margin of -10.6% compared to Tarsus Pharmaceuticals, Inc.'s net margin of -5008.35%. Tarsus Pharmaceuticals, Inc.'s return on equity of -27.56% beat Precigen, Inc.'s return on equity of -711.28%.

Tarsus Pharmaceuticals, Inc. has a consensus price target of $87.50, signalling upside risk potential of 7.49%. On the other hand Precigen, Inc. has an analysts' consensus of $8.50 which suggests that it could grow by 96.76%. Given that Precigen, Inc. has higher upside potential than Tarsus Pharmaceuticals, Inc., analysts believe Precigen, Inc. is more attractive than Tarsus Pharmaceuticals, Inc..

Tarsus Pharmaceuticals, Inc. has a beta of 0.745, which suggesting that the stock is 25.508% less volatile than S&P 500. In comparison Precigen, Inc. has a beta of 1.162, suggesting its more volatile than the S&P 500 by 16.189%.

Tarsus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precigen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tarsus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Precigen, Inc. pays out -- of its earnings as a dividend.

Tarsus Pharmaceuticals, Inc. quarterly revenues are $118.7M, which are larger than Precigen, Inc. quarterly revenues of $2.9M. Tarsus Pharmaceuticals, Inc.'s net income of -$12.6M is higher than Precigen, Inc.'s net income of -$146.3M. Notably, Tarsus Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Precigen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tarsus Pharmaceuticals, Inc. is 9.05x versus 203.77x for Precigen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.